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CASE REPORT
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after a Single Session of Fractionated CO2 Laser Ablation: 
A Method to Enhance Percutaneous Drug Delivery
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1Department of Dermatology and Cutaneous Biology Research Institute, Yonsei University College of Medicine, 2Scar Laser and Plastic 
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Tuberous sclerosis complex (TSC) is an autosomal dominant 
neurocutaneous disorder with an incidence of approximate-
ly 1 in 5,000 to 10,000 live births. TSC has various clinical 
manifestations such as multiple hamartomas in systemic or-
gans, including the skin. Angiofibromas are the most com-
mon skin lesions in patients with TSC. Although benign, an-
giofibromas develop in childhood and puberty, and can be 
psychosocially disfiguring for patients. Skin lesions in TSC, 
specifically angiofibromas, have no significant risk of malig-
nant transformation after puberty; thus, they require no treat-
ment if not prominent. However, the presentation of TSC is 
important owing to its impact on patient cosmesis. Surgical 
treatment and laser therapy are the mainstream treatments 
for angiofibromas. Although the evidence is limited, topical 
mammalian target of rapamycin inhibitors such as sirolimus 
(rapamycin) are effective in facial angiofibroma treatment. 
We describe an adult patient with an angiofibroma who had 
an excellent response to treatment with topical rapamycin af-
ter a single session of carbon dioxide (CO2) laser ablation. 
The patient showed no sign of relapse or recurring lesions for 
a year. CO2 laser ablation may serve as a new paradigm of 
treatment for angiofibromas in TSC. Since the selection of la-
ser devices can be limited for some institutions, we suggest 
a rather basic but highly effective approach for angiofibroma 
treatment that can be generally applied with the classic CO2 
device. (Ann Dermatol 31(5) 555∼558, 2019)
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INTRODUCTION
Tuberous sclerosis complex (TSC) is an autosomal domi-
nant neurocutaneous disorder characterized by pleomor-
phic features of systemic organs. The skin is the most com-
monly affected organ system with up to 90% involve-
ment1. Facial angiofibroma is the main feature of this dis-
ease, affecting approximately 75% of patients. Angiofibro-
mas appear in early childhood (ages 2∼5 years) as red 
papules and increase in number and size throughout pub-
erty2,3.
To date, various treatment modalities for angiofibromas 
have been proposed, including surgical excision, curettage, 
dermabrasion, electrocautery, and laser ablation4-7. Despite 
the use of rigorous approaches to completely remove the 
lesions, the outcomes have been suboptimal with a high 
recurrence rate8,9. In addition to improved understanding 
of the genetic and molecular pathogenesis of the disease, 
prominent vascular proliferation due to an increased vas-
cular endothelial growth factor (VEGF) level and mamma-
lian target of rapamycin (mTOR) overactivation were not-
ed in angiofibromas. Rapamycin binds to mTOR with high 
specificity and represses the VEGF output by inhibiting the 
J Oh, et al
556 Ann Dermatol
Fig. 1. Improvement of facial angio-
fibroma lesions in a 20-year-old pa-
tient with tuberous sclerosis com-
plex during rapamycin therapy after
a single session of CO2 laser abla-
tion. Left panels, labeled 0: before 
the administration of laser ablation. 
Pronounced improvement was ob-
served at 1, 3, 6, and 8 months after
the start of systemic rapamycin 
therapy after a single session of CO2
laser ablation.
hypoxia-inducible factor and endothelial cell prolifer-
ation10,11. Additionally, it suppresses T-cell activity and an-
tibody production, resulting in decreased keratinocyte 
proliferation and inflammation12.
The use of topical rapamycin has been proposed and 
shown successful outcomes for both preventing and re-
ducing angiofibroma lesions12. The current general con-
sensus among the considered studies suggests that topical 
rapamycin is an efficient therapy for facial angiofibromas, 
providing improvement in 94% of cases8. Unlike pediatric 
patients who can benefit from preventive measures with 
the early application of topical rapamycin, adult patients 
with an already fully developed disease that includes nod-
ular lesions report poor outcomes with monotherapy13.
We describe the case of an adult patient who showed an 
excellent clinical response after a single session of carbon 
dioxide (CO2) laser ablation and continued use of 0.2% 
topical rapamycin for maintenance.
CASE REPORT
A 20-year-old Korean male previously diagnosed as hav-
ing TSC was referred to the dermatology department for 
the treatment of extensive angiofibromas on his face. His 
DNA test revealed mutations in TSC2. He presented with 
scattered and grouped lesions of facial angiofibromas of 
various sizes and thicknesses. Additionally, periungual fi-
broma and hypomelanotic macules were noted. Regarding 
the systemic features of the disease, multiple hamartomas 
of the heart and kidney were noted.
One year before visiting Scar Laser and Plastic Surgery 
center, the patient underwent ablative laser treatment for 
cheek lesions. However, most of the lesions recurred 
within a few months during the late pubertal period, and 
wound healing was delayed for large nodules.
He underwent extensive CO2 laser ablations for all facial 
lesions. We used a starting fluence between 100 and 150 
mJ of continuous CO2 pulses (eCO2TM; Lutronic, Goyang, 
Korea), and multiple passes were performed until the le-
sions were flattened. To improve the absorption of topical 
rapamycin and wound healing, a fractional CO2 laser was 
additionally applied on the whole face. The treated areas 
were cooled with ice packs for 10∼15 minutes, and top-
ical rapamycin was directly applied. Thereafter, a foam 
dressing was applied for protection and maintained for 1 
day. To minimize the risk of post-inflammatory hyperpig-
mentation (PIH), sunscreen with broad-spectrum ultraviolet 
(UV) A and UVB protection was prescribed.
The patient returned to the clinic on the following day 
without any complication. He was encouraged to use top-
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Table 1. Facial Angiofibroma Severity Index (FASI) scores after 
treatment
Parameter
FASI score
Pretreat-
ment
1 
month
3 
months
6 
months
8 
months
Erythema 2 1 1 0 0
Size 3 2 1 1 1
Extension 3 3 3 2 2
ical rapamycin once a day afterward. He regularly visited 
the clinic every 2∼3 months, and no sign of recurrence or 
irritation was noted at 1 year after laser ablation (Fig. 1). 
We received the patient’s consent form about publishing 
all photographic materials. Additionally, there were no 
signs of hypertrophic scarring or delayed wound healing 
during the follow-up period (Table 1).
DISCUSSION
The advent of topical rapamycin has dramatically changed 
the paradigm of angiofibroma treatment. However, topical 
rapamycin monotherapy is insufficient for fully developed 
lesions in adults. Various types of lasers have been popu-
lar options, and many studies have reported successful re-
sults with CO2, copper vapor, argon, pulsed dye, potas-
sium-titanyl-phosphate, and Nd:YAG lasers6,14-16. For flat-
tened lesions, lasers targeting the vascular structure or 
melanin pigments may generate sufficient energy to de-
stroy individual lesions with photothermolysis. However, 
full-thickness ablation of abnormal keratinization and un-
derlying fibrosis is indispensable for bulky lesions. The 
CO2 laser is one of the most widely used lasers in derma-
tology17. CO2 lasers with a 10,600-nm wavelength target 
the water component of tissues. As a single CO2 laser can 
be modulated to cause tissue reactions of incision, ex-
cision, vaporization, and coagulation, it can successfully 
have a debulking effect even for extensive lesions.
Unlike previous reports showing that the CO2 laser caused 
hypertrophic scarring in a considerable percentage of pa-
tients6, we did not experience scarring or delayed wound 
healing in our patient. This outcome can be partially due 
to the fractionated application of the CO2 laser after abla-
tion of single lesions. The ablative fractional CO2 laser can 
compensate for the lack of specific photothermolysis in 
CO2 laser monotherapy. By thoroughly producing micro-
thermal zones on the CO2-ablated surface, columns of 
thermal damage cause collagen remodeling and promote 
wound healing18.
PIH can occur at any age and in any skin type, and it has 
no sex preference. However, this type of hypermelanosis 
is more common in patients with Fitzpatrick skin types IV∼
VI. Previous research showed that the degrees of erythema 
and pigmentation correlated linearly after UVB irradi-
ation18. Additionally, crusts after laser treatment protect 
the wound and help prevent the development of PIH after 
laser treatment. To minimize the risk of PIH, it is neces-
sary to avoid early removal of the crusts and to apply 
sunscreen with broad-spectrum UVA and UVB protection.
We also postulate that topically applied rapamycin could 
have contributed to normal wound healing after full-thick-
ness ablation. mTOR is a regulator of cell growth and sur-
vival, and acts as a mediator of inflammatory and fibrotic 
processes. In recent in vitro reports, the mTOR signaling 
pathway was shown to cause proliferation of abnormal fi-
broblasts, causing pathologic scars19,20. Therefore, topical 
rapamycin can induce a synergistic effect of angiogenesis 
inhibition for the recurrence of angiofibroma lesions and 
abnormal scarring repression after CO2 laser ablation. Not-
ably, even with a 0.2% preparation, topical rapamycin did 
not cause immediate irritation when directly applied on 
the laser-ablated surface.
Angiofibromas in TSC significantly affect patients’ quality 
of life by causing psychosocial comorbidities. It can be es-
pecially burdensome for late adolescent and young adult 
patients who have already developed extensive lesions 
throughout puberty. Despite the use of expensive appro-
aches, there is no sustained efficacy in the long term and 
the risks of complications such as scarring remain. TSC is 
a predominantly inherited genetic condition that occurs in 
all races and ethnic groups. We concede with current re-
ports describing the successful outcomes of various laser 
devices. However, the selection of laser devices can be 
limited for some institutions. Therefore, we suggest a rath-
er basic but highly effective approach for angiofibroma 
treatment that can be generally applied with the classic 
CO2 device.
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